{
  "doc_id": "CT-17321_LENVIMA_PIC_EI_Avis3_CT17321",
  "created_date": "2019",
  "country": "FR",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "the the Commission: 2019 2019 ’2019. 2019.",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "hard hard capsules",
      "text": "capsules capsules (CIP: 4 4 1)",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "hard hard capsules",
      "text": "capsules capsules (CIP: 5 5 8) Laboratory EISAI",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "L01XE29 L01XE29 (protein kinase inhibitor)",
      "text": "Security Security (CSS L.162-17) Communities Communities (CSP L.5123-2) “carcinoma carcinoma (HCC) treatment. treatment.” this this demonstration: population population (or or 1) non-patient-dated dated 05/03/function function (stage stage A), carcinoma carcinoma (HCC) treatment treatment (the the CPR).’ DOSAGE “mg mg (4 4 mg) mg mg (once once daily) a a day) stage stage (stage stage B). invasion invasion and/involvement involvement (stage stage C), recommended. recommended.",
      "start_page": 1,
      "end_page": 5
    },
    {
      "heading": "1. 1. Method",
      "text": "Study REFLECT-304 (E7080-G000-304) phase phase study; phase phase study: study study – diseasePathoma diseasePathoma (HAS) Disease Disease (ASALD) the the following: 1 mg/day, 60 kg: 8 mg/ day; 2 mg/week; . 3 mg/month; .3 mg/year; .4 mg/hour; .5 mg/time; .8 mg/night; .6 mg/minute; .1 mg/kg; survival survival (OS) of of cause* cipal * outcome outcome endpoints: endpoints endpoints (this this document) rate rate (this this paper) . endpoint endpoint (this this report) ; endpoint endpoint ; (this this article) per-protocol per-protocol (alyse alyse treatment); population population (actually actually received) manner manner (for superiority). response response (ORR) the the Cochran-amendment amendment (6 January 2014) criteria criteria (etc. etc.), questionnaire questionnaire AORTC-endpoint endpoint (statistical statistical analysis) survival survival (3 3 months).",
      "start_page": 7,
      "end_page": 10
    },
    {
      "heading": "2 2 Results",
      "text": "study study (median therapy) group group (21.4D) group group (21.5D) group group (14.0D) group group (21.0D) . group group (20.9D) group group (10.0D) of of 5% (1. 1.08). 3 3 : %___MD_ ___MD_ %MI ___Empty_%_ %ME_ %2M_ 2M_ %MD_%%_%%_Me_%+%_0_% >%_Relapse ___M_%> (n 476) n 575%1217) n(%) 10. 10.1% frequent frequent (>2% treatment treatment group) common common (vs. %) __MEDTERM0_ __MEDTERM0_ (2.3 percent) 1_MEDTERm1_ 1_MEDTERm1_ (0.8 percent) treatment treatment were: hypertension (1.5 % 1 1 %), encephalopathies (vs. vs. 0%), increased bilisprubin (vs. vs.47%), hepatic failure (6 6 percent) pain pain (Special Special Interest).",
      "start_page": 10,
      "end_page": 18
    },
    {
      "heading": "from from PSURs",
      "text": "report report (PSUR) this this period: - reported, reported, - identified, identified, - pneumonitis, pneumonitis, dysphagia",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "\" Undesirable Undesirable effects",
      "text": "collected collected [...] with with [...] reactions reactions (occurring in 30% of patients) are: hypertension (44.0%), diarrhea (38.1%), decreased appetite (30%).",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "the the PMP",
      "text": "group group (median age) secondary secondary group; tertiary tertiary group; 7 7 % of 0,7% 6 6 % clinical clinical trial; 3,6% clinical clinical study; 3, 3,7% of QDR_REJ; QR_REG 2,6% of . 30.3%) _0, _0,8% vs. 14.5% group) all, all, considering: - non-inferiority non-inferiority (the the superiority) survival, survival, - as as robust; - disease disease (BCLC_D), recommended. recommended. LENVIMA'non-inferiority non-inferiority - superiority superiority - limitations. limitations.",
      "start_page": 19,
      "end_page": 22
    },
    {
      "heading": "L01XE29 L01XE29 (protein kinase inhibitor)>",
      "text": "Row 1: Row 2: lenvatinib Row 3:",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "L01XE29 L01XE29 (protein kinase inhibitor)>",
      "text": "Row 1: Code ATCL01XE29 (protein kinase inhibitor) Row 2: Row Row 3: safety safety (CSS L.162-17) Communities (CSP L.5123-2) Row 4: Relevant indication‘carcinoma carcinoma (HCC).’",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "L01XE29 L01XE29 (protein kinase inhibitor)>",
      "text": "Row 1: Row 2: à à l'arge dans l'Row Row 3:",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "L01XE29 L01XE29 (protein kinase inhibitor)> (from previous page)",
      "text": "Row1: Relationship of non-Row1:the the row:the the rrow_Equipment: Row2:row. row. Row3:",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "L01XE29 L01XE29 (protein kinase inhibitor)> (from previous page)",
      "text": "Row 1: SMR",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "L01XE29 L01XE29 (protein kinase inhibitor)> (from previous page)",
      "text": "Row 1: ISP",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "L01XE29 L01XE29 (protein kinase inhibitor)> (from previous page)",
      "text": "Row 1: Row Row 2: Strategy Row 3: therapeutic",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "L01XE29 L01XE29 (protein kinase inhibitor)> (column column 1)",
      "text": "Row 1: Row 2: SMR Row 3: row 4: row 5: ASMR Row 6: Row 7: ISP Row 8: ISP Row 9:",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "L01XE29 L01XE29 (protein kinase inhibitor)> (column column 2)",
      "text": "Row 1: Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: a Row 12: Row 13: ue Row 14:",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "L01XE29 L01XE29 (protein kinase inhibitor)> (column column 3)",
      "text": "Row 1: CrowD_RowD_Result_Raw_Rown_RrowM_ROW_R:RowM_RR_Rh_RH_RHO_Rhodotype_R row_RW_Rw_RRh:RR_L_R.RH:rh_NRR_RJ_R_S_R+Rh,R: Rj_R0Rw: RH_T_Rv_Rx_R>RhRn_Rm_R/Rh;Rl_Rov_R1_R2_Rc_R(Rht_R-Rh r_R :R to_R*R::E:I_Rp_Ror_Rb_Rof_Rhe_Rop_RB:O_R,r:of_R of_R for:Ro:RC: F_R3Rhan_R from_Rol_Rk_R >R:R:",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "L01XE29 L01XE29 (protein kinase inhibitor)> (column column 3)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "L01XE29 L01XE29 (protein kinase inhibitor)> (from previous page)",
      "text": "Row 1: AMMInitial date (centralised procedure) : 28/05/indication indication (this this notice): 20/08/the the AMM: profile profile (including hepatic toxicity) trials. trials.",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "L01XE29 L01XE29 (protein kinase inhibitor)> (from previous page)",
      "text": "Row 1: mg. mg. Row: mg. mg.?Resolution 2 mg?Row Row 2: Dose 4 mg?1 1 mg?effects. effects.",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "L01XE29 L01XE29 (protein kinase inhibitor)> (from previous page)",
      "text": "Row 1: NAMECPT*Row Row 2: Row Row 3: (INN)identicalIndicationSMRload Row 4: advice(Libellé) Row 5: Laboratoryyes/noRow 6: Row 7: NEXAvar (_MEDTERM0_T)",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "1 1 Method>",
      "text": "Row 1: DRAFT Row 2: CountryYES/NOPopulation(s) Row 3: Row Row 4: Row Row 5: GermanyYes",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "1 1 Method>",
      "text": "Row 1: Row Row 2: al. al., Row Row 3: Reference Row 4: unresectable hepatocellular carcinoma: line line 5: Figure below): - inclusion inclusion period; - analysis analysis date; - date. date.",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "1 1 Method> (from previous page)",
      "text": "Row 1: Row 2: Pathogens: AASLD AASLD (Liver Liver Diseases) B B (chemotherapy chemotherapy treatment) baseline baseline ( 60 kg: 12 mg/day; 60kg: 8 mg/ day)* Control group: day day (D1D28)** the the patient’consent. consent.",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "1 1 Method> (column column 1)",
      "text": "Row 1: Row 2: Row 3: Principau Row 4: included Row 5: row 6: row 7: principau row 8: Row Row 9:",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "1 1 Method> (column column 2)",
      "text": "Row 1: Row 2: Row 3: Row Row 4: ion Row 5: Row 6: Row 7: Row Row 8: nclusi Row 9: Row 10: Row 11: ents Row 12: Row 13:",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "1 1 Method> (column column 3)",
      "text": "Row 1: Row 2: Pathogens: AASLD AASLD (Liver Liver Disease) status status (anti-chemocardial anti-chemocardial therapy). baseline baseline ( 60 kg: 12 mg/day; 60kg: 8 mg/ day)* Control group: day day (D1D28)** the the patient’consent. consent.",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "1 1 Method> (from previous page)",
      "text": "Row 1: of of 1: 1 (_MEDTERM0_ vs. __MEDTROM1__) and stratified to: Cycle region: versus versus CW’Regularity Regularity range: *rangeCohormonalPast rangeCohormonalPast range: 5D 5D ; the the intent-to-treat population (nonrandomization nonrandomization group). population population (for for 95% treatment treatment dose)",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "1 1 Method> (column column 1)",
      "text": "Row 1: Row 2: Row Method 3: randomization Row 4: row 5: row 6: Row Row 7: Row Row 8: line 9:line 10:Row Row 11: judgment Row 12:",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "1 1 Method> (column column 2)",
      "text": "Row 1: of of 1:1 (_MEDTERM0_ vs. __MEDTROM1_) and stratified to: - First region-Pattern-Paterity-Patterness-Pathierty-Paperage-Patrety-Results-Tyre-Patrimony-Relationship-Preparation-Paternity-Station-Patorty-Tie-Pasterage-Tice-Tryness-Thyrevalness-Case-Tority-Tentification-Tatio-Tary-Tide-Têtient-Tété-Texation-Tuety-Earness-Patioe-Tif-T*-Tearence-Tate-Tatival-Tage-Ratio-Natio-Latious-Tée-Tair-Tease-Tailway-Trace-Tité-Tier-Trailness-Reas-Tois-Tase-Statioal-Tace-T-Téléf-Tae-Thematic-Tariement-Tation-to-T+Tatio.-Tee-Térature-Teur-Tet-Tise-T’-T;-Tow-Tick-Tu-Tific-Tover-Tacy-Tap-Tès-RT-T >-Tar-Terty-Pratio-R-Tare-Tax-T e-Tô-T'-Tray-Taire-Tau-T>T-Rea-T.-To-Tale-Tur-T/T-Rative-Thos-Tacation-Reach-Thrism-Tiness-Train-Tivation-Coar-Re-T Path-T The-Tion-T o-Tien-Tough-Ting-Tero-Tural-Tle-Tio-Teach-Teh-Tars-Tone-Tais-T are-T2-Tru-Tition-Teration-T(T-Ro-Test-T-Tane-Trop-Town-Tees-Tav-Tai-Tour-Taro-secondary secondary endpoints: residual residual endpoints; endpoints endpoints (this this document) 10 10 (this this paper) Row Row 12: the the intent-to-treat population (randomization randomization group). population population (PP population – treatment treatment dose) population population (i.e.",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "2 2 Results>",
      "text": "Row 1: 0. 0.06M_; CI [0.57; 0.83]. of of 95% exploratory exploratory (total total endpoint).",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "2 2 Results> (from previous page)",
      "text": "Row 1: (n 478)(N 774)(R 357) (R ) Row 3: , Row: 0 0 , 0 0 .",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "2 2 Results> (column column 1)",
      "text": "Row 1: Row Row 2: (n478) Row 3: Age - years",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "2 2 Results> (column column 1)",
      "text": "Row 1: Gender – n (%)",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "2 2 Results> (column column 1)",
      "text": "Row 1: Geographic region – n (%)",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "2 2 Results> (column column 1)",
      "text": "Row 1: ECOG PS – n (%)",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "2 2 Results> (column column 1)",
      "text": "Row 1: diagnosis diagnosis - months",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "2 2 Results> (column column 1)",
      "text": "Row 1: Etiology",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "2 2 Results> (column column 1)",
      "text": "Row 1: BCLC stage – n (%)",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "2 2 Results> (column column 1)",
      "text": "Row 1: Child-Pugh score – n (%)",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "2 2 Results> (column column 1)",
      "text": "Row 1: Vascular invasion and/or extra-hepatic metastases",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "2 2 Results> (column column 1)",
      "text": "Row 1: Underlying cirrhosis – n (%)*",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "2 2 Results> (column column 1)",
      "text": "Row 1: Alpha-fetoproteine concentration (AFP)",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "2 2 Results> (column column 1)",
      "text": "Row 1: treatment treatment – n (%)",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "2 2 Results> (column column 2)",
      "text": "Row 1: 319 319 (67,0) 9 10: 301 (90): 301 (92),5 5 . .",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "2 2 Results> (column column 3)",
      "text": "Row 1: Total Row 2: (n954) Row 3: Row 4: Row Row 5: row 6: 706 (84.4) 148 (6.5) row 7: lane 8: 314 (32.9) 640 (67.1) 9: line 10: 605 (63.4) 262 (227) (327) (36.6) row 11: 12:",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "2 2 Results> (from previous page)",
      "text": "Row 1: Lenvatinib (N 478)__MESTERM1__ (n 476) Row 2: N (%)N(%)Row 3: Row: Row 3: progression156 progression156 (32.6)184 (38.7) Row 4:Row Row 5: 1100 (20.92)N (40.92.10)8",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "2 2 Results> (from previous page)",
      "text": "Row 1: Row Row 2: Unwanted Event(n476)(N475) Row 3: n(%)n(0) Row 4: Hypertension201 (42.2)144 (30.3) Row 5: DiarrhoeaPerceived184 (38.7)125:2",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "2 2 Results> (from previous page)",
      "text": "Row 1: Row Row 2: Serious adverse event(n476)(N475) Row 3: n (%)n% Row 4: Hepatic encephalopathy21 (4.4)3 (0.6) Row 5: Hepatic impairment14 (2.12)",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "2 2 Results> (from previous page)",
      "text": "Row 1: Row Row 2: to to death(n476)(N475) Row 3: nn Row 4: Row Row 5: Sepsis10 row 6: cerebral haemorrhagia/gastro-1+0",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "heading heading \" Undesirable Undesirable effects>",
      "text": "Row 1: Row Row 2: of of interest(n476)( n475) Row 3: n (%)n% Row 4: Hepatotoxicity227 (47.7)198 (41.7) Row 5: Hypertension212 (244.5)147 (29.9) Row 6:",
      "start_page": 18,
      "end_page": 18
    }
  ]
}